RT Journal Article
SR Electronic
T1 Convalescent plasma treatment of severe COVID-19: A matched control study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.20.20102236
DO 10.1101/2020.05.20.20102236
A1 H. Liu, Sean T.
A1 Lin, Hung-Mo
A1 Baine, Ian
A1 Wajnberg, Ania
A1 Gumprecht, Jeffrey P.
A1 Rahman, Farah
A1 Rodriguez, Denise
A1 Tandon, Pranai
A1 Bassily-Marcus, Adel
A1 Bander, Jeffrey
A1 Sanky, Charles
A1 Dupper, Amy
A1 Zheng, Allen
A1 Altman, Deena R.
A1 Chen, Benjamin K.
A1 Krammer, Florian
A1 Mendu, Damodara Rao
A1 Firpo-Betancourt, Adolfo
A1 Levin, Matthew A.
A1 Bagiella, Emilia
A1 Casadevall, Arturo
A1 Cordon-Cardo, Carlos
A1 Jhang, Jeffrey S.
A1 Arinsburg, Suzanne A.
A1 Reich, David L.
A1 Aberg, Judith A.
A1 Bouvier, Nicole M.
YR 2020
UL http://medrxiv.org/content/early/2020/05/22/2020.05.20.20102236.abstract
AB Background Since December 2019, Coronavirus Disease 2019 (COVID-19) has become a global pandemic, causing mass morbidity and mortality. Prior studies in other respiratory infections suggest that convalescent plasma transfusion may offer benefit to some patients. Here, the outcomes of thirty-nine hospitalized patients with severe to life-threatening COVID-19 who received convalescent plasma transfusion were compared against a cohort of retrospectively matched controls.Methods Plasma recipients were selected based on supplemental oxygen needs at the time of enrollment and the time elapsed since the onset of symptoms. Recipients were transfused with convalescent plasma from donors with a SARS-CoV-2 (severe acute respiratory disease coronavirus 2) anti-spike antibody titer of ³1:320 dilution. Matched control patients were retrospectively identified within the electronic health record database. Supplemental oxygen requirements and survival were compared between plasma recipients and controls.Results Convalescent plasma recipients were more likely than control patients to remain the same or have improvements in their supplemental oxygen requirements by post-transfusion day 14, with an odds ratio of 0.86 (95% CI: 0.75∼0.98; p = 0.028). Plasma recipients also demonstrated improved survival, compared to control patients (log-rank test: p = 0.039). In a covariates-adjusted Cox model, convalescent plasma transfusion improved survival for non-intubated patients (hazard ratio 0.19 (95% CI: 0.05 ∼0.72); p = 0.015), but not for intubated patients (1.24 (0.33∼4.67); p = 0.752).Conclusions Convalescent plasma transfusion is a potentially efficacious treatment option for patients hospitalized with COVID-19; however, these data suggest that non-intubated patients may benefit more than those requiring mechanical ventilation.Competing Interest StatementDr. Krammer reports that patent applications have been filed for the assay used to select plasma donors, and Mount Sinai has licensed its use to several companies. Dr. Aberg reports grants and personal fees from Gilead, grants and personal fees from Merck, grants and personal fees from Janssen, personal fees from Theratech, personal fees from Medicure, grants from Regeneron, grants and personal fees from Viiv, outside the submitted work. All other authors have nothing to disclose.Funding StatementNo external funding was received for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available from the corresponding author upon reasonable request.